Skip to content

Tarsus Pharmaceuticals

US · TARS #2389 by market cap Listed 2020
73.01 -4.66 -6.00%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Valuation each multiple against its own 5-year range

P/B ratio 38.05 Expensive vs history 100th percentile
5-year average 5.35 · #496 of 514 in Biotechnology
P/E ratio -5.06 Expensive vs history 90th percentile
5-year average -18.42 · forward -48.79
P/S ratio 5.80 Cheap vs history 10th percentile
5-year average 19.44 · forward 4.47 · #125 of 389 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Tarsus Pharmaceuticals (TARS) 3.60B -4.60 34.60 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value69.36 Economic moatNone UncertaintyVery High

Trading 5.0% above Morningstar's fair value estimate.

Fair value

Tarsus Pharmaceuticals Inc receives a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 16% premium over our quantitative fair value estimate of $69.36 per share; however, this estimate should be taken with a pinch of salt due to its very high uncertainty rating.

The company's valuation metrics weaken our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its book value yield of 3.1%, which ranks in the bottom 10% globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which contributes to our view that shares are expensive.

The firm's liquidity is an additional cause for concern. Excessive liquidity may suggest inefficient capital use or limited investment opportunities. The firm's median trading volume over the past 60 days, a core component of liquidity, sits in the top 40% compared with global peers. High trading volumes could indicate a sharp change in business model or a new growth trajectory of the business. This characteristic further promotes our unfavorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

Economic moat

The company's quantitative economic moat rating of none suggests any excess returns could erode quickly as competition arrives. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 20:02:22 · For reference only, not investment advice and not tailored to your situation.

Tarsus Pharmaceuticals discussion 0 comments

Add a comment